|Bid||0.0000 x 1200|
|Ask||0.0000 x 1000|
|Day's Range||2.6200 - 2.7600|
|52 Week Range||2.0400 - 6.4700|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021 - May 17, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.57|
Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has recommenced patient screening in a Phase 2 study of NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinson’s disease and dementia with Lewy bodies. The company anticipates reporting data from this study in the second half of 2022.
Aptinyx Inc. ( NASDAQ:APTX ) shareholders might be concerned after seeing the share price drop 22% in the last month...
At this time, I would like to turn the call over to Nick Smith, vice president of corporate development and investor relations of Aptinyx. On today's call, Norbert Riedel, our chief executive officer, will discuss our business and clinical development progress, and Ashish Khanna, our chief financial officer, and the chief business officer will review our financial results.